Sionna Therapeutics Inc. (SION)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path
Sionna Therapeutics NASDAQ: SION said its PreciSION CF Phase 2a proof-of-concept study of SION-719 added to Trikafta did not meet its key activity endpoint, prompting the company to discontinue development of SION-719 as an add-on to standard of care for cystic fibrosis.
Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript
Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript
Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment
Sionna Therapeutics targets cystic fibrosis with a novel NBD1 stabilization mechanism, aiming to enhance CFTR function beyond current standards. SION-719 as an add-on to Trikafta and SION-451 dual combinations both approach pivotal clinical readouts in summer 2026, offering dual strategic paths. Sionna's $289.9M cash runway extends to 2028, supporting critical proof-of-concept milestones without near-term financing risk.
Sionna Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 1 | $41 | $47.13 | $6.13 | 14.95% |
| NA Nizar Araji National Bank Of Canada /FI/ | 2 | $87.98 | $102.08 | $14.1 | 16.03% |
| BG Bart Gancher Intech Investment Management LLC | 5,218 | $154,669.57 | $266,326.73 | $111,657.16 | 72.19% |
 John H. Burbank III Passport Capital LLC | 400,000 | $4.18M | $2.58M | -$1.6M | -38.24% |
 Point72 Asset Management LP Point72 Asset Management LP | 49,328 | $1.98M | $318,658.88 | -$1.66M | -83.89% |
Sionna Therapeutics Inc. (SION) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sionna Therapeutics Inc. ever had a stock split?
Sionna Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael Cloonan CEO | NASDAQ (NMS) Exchange | 829401108 CUSIP |
| US Country | 59 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Sionna Therapeutics, Inc. is a pioneering biopharmaceutical company focused on developing innovative therapies to improve the lives of patients suffering from cystic fibrosis (CF). By addressing the fundamental issues related to the malfunctioning of the cystic fibrosis transmembrane conductance regulator (CFTR), Sionna aims to enhance treatment paradigms for individuals affected by this genetic disorder. With a strong commitment to advancing research and developing effective medications, Sionna Therapeutics is positioned at the forefront of cystic fibrosis treatment.
Products and Services
- CFTR Modulators
These are tailored medications designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator protein, addressing the root cause of cystic fibrosis. By correcting the defective CFTR protein, these modulators aim to improve lung function and reduce the frequency of pulmonary infections.
- Combination Therapies
Sionna Therapeutics is also focused on developing combination therapies that incorporate multiple drugs to target various aspects of cystic fibrosis. These therapies can enhance treatment efficacy and provide comprehensive management for patients, addressing both the genetic and symptomatic elements of the disease.
- Patient Support Programs
In addition to drug development, Sionna offers patient support programs aimed at educating and guiding patients through their treatment journey. These programs include resources for disease management, access to clinical trial information, and avenues for community support to empower patients and their families.
- Research and Development Collaborations
Sionna Therapeutics actively seeks collaborations with academic institutions and research organizations to further advance the understanding of cystic fibrosis. By engaging in collaborative R&D, the company aims to explore new avenues of treatment and foster innovation in the biopharmaceutical landscape.
